Angion Biomedica Corp. Stock News

Angion (ANGN) inks a definitive merger agreement with privately-held Elicio Therapeutics. The combined company's lead pipeline candidate will be ELI-002, a therapeutic cancer vaccine targeting mKRAS-d

ENTX, STIM, FN, ANGN and FUTU have been added to the Zacks Rank #1 (Strong Buy) List on November 16, 2022.

PHX, BEPC, ANGN, CXM and GMBL have been added to the Zacks Rank #1 (Strong Buy) List on October 25, 2022.

Angion Biomedica Corp (NASDAQ: ANGN) has discontinued the JUNIPER Phase 2 trial of ANG-3070, an oral tyrosine kinase inhibitor, in primary proteinuric kidney diseases, specifically focal segmental

Here's what you need to know about trading penny stocks on June 1st The post What to Know About Buying Penny Stocks on June 1st appeared first on Penny Stocks to Buy, Picks, News and Information | Pen

Let us take a look at some drug/biotech stocks, ANGN, APLT, BOLT, IKNA and LABP, which are poised to beat on first-quarter earnings.

UNIONDALE, N.Y., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Angion Biomedica Corp. (NASDAQ:ANGN), a biopharmaceutical company focused on the discovery, development, and commercialization of novel small molecule therapeutics to address fibrotic diseases, today announced participation in two upcoming investment conferences.

Angion Biomedica Corp. (NASDAQ:ANGN) saw a significant decline in short interest during the month of November. As of November 30th, there was short interest totalling 283,800 shares, a decline of 26.4% from the November 15th total of 385,800 shares. Based on an average daily trading volume, of 273,300 shares, the days-to-cover ratio is currently 1.0 []

In the last trading session, 1.29 million shares of the Angion Biomedica Corp. (NASDAQ:ANGN) were traded. Most recently the companys share price was $2.61, and it changed around -$0.88 or -25.21% from the last close, which brings the market valuation of the company to $84.25M. ANGN currently trades at a discount to its 52-week high A Business Review Of Angion Biomedica Corp. (NASDAQ: ANGN) And Growth Forecast Read More »

Angion's (ANGN) phase II study evaluating ANG-3777 in cardiac surgery-associated acute kidney injury fails to achieve the primary endpoint.

Angion Biomedica (NASDAQ:ANGN) had its price objective reduced by analysts at Oppenheimer from $15.00 to $8.00 in a report issued on Friday, The Fly reports. The firm presently has an outperform rating on the stock. Oppenheimers price target would indicate a potential upside of 206.51% from the companys current price. A number of other equities []

Here''s a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Angion Biomedica''s ANG-3777 Does Not Meet Primary Endpoint In Mid-Stage Study In…

Regulatory News: This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211209006035/en/ AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR Vifor Pharma and Angion Biomedica Corp. (NASDAQ: ANGN) today announced results from the exploratory phase-II GUARD trial of Angion’s ANG-3777 in patients undergoing cardiac surgery involving cardiopulmonary